Skip to content
Calculator
Comparison

Peptides That Raise Testosterone: Kisspeptin, Gonadorelin and hCG Compared

Last updated: October 27, 2026 · 10 min read · By the Grey Peptides Editorial Board

Rows of blood sample vials in a laboratory, ready for analysis
Photo by Tahir Xəlfəquliyev on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • The three act at different levels of one chain: kisspeptin on the brain's GnRH neurons, gonadorelin on the pituitary, hCG directly on the testis. Where a man's problem sits decides which, if any, can help.
  • Rhythm matters as much as the molecule. Continuous GnRH shuts the pituitary down rather than stimulating it, and in a 2026 trial continuous kisspeptin lost its effect on LH and FSH within five days while intermittent dosing held for twelve.
  • hCG has the clearest data for the question most men ask: in men given testosterone, low-dose hCG kept testicular testosterone near normal when it otherwise fell by 94%.
  • hCG is approved, among other uses for selected men with hypogonadism caused by pituitary deficiency; its labels state in capitals that it has not been shown to work for weight loss. Gonadorelin's US human brands are discontinued. Kisspeptin is not approved.
  • All three are banned in male athletes at all times, in section S2.2.1 of WADA's 2026 and 2027 Lists.

One chain, three places to push

Testosterone in men is the last step of a relay. Kisspeptin acts on GnRH neurons in the hypothalamus, driving pulsatile release of gonadotropin-releasing hormone (GnRH) 1; GnRH acts on the pituitary, which releases luteinising hormone (LH) and follicle-stimulating hormone (FSH) 1; LH stimulates the Leydig cells of the testis to make testosterone 1. Testosterone inside the testis is far higher than in the blood, which researchers take to mean a high concentration is needed for normal sperm production 2.

The three peptides in this article push on that relay at different points. Kisspeptin acts at the top, on the GnRH neurons. Gonadorelin is GnRH itself, made synthetically, and acts on the pituitary. hCG skips the brain and pituitary entirely: it acts on the same receptor as LH, directly on the testis.

That ordering is the whole comparison in miniature. A peptide can only work if every step below the one it acts on still works. Kisspeptin needs functioning GnRH neurons, pituitary and testes; gonadorelin needs a functioning pituitary and testes; hCG needs only the testes. And none of them can help a man whose testes themselves have failed, which is why the first question a clinician asks is where in the chain the problem sits.

Side by side

Status columns are as of October 27, 2026 1. Evidence grades come from our encyclopedia and reflect all human evidence for each compound.

KisspeptinGonadorelin (GnRH)hCG
Acts onGnRH neurons in the hypothalamusThe pituitaryThe testis, through the LH receptor
Raises LH and FSHYes, in human studiesYes, when given in pulsesNo — it acts on the LH receptor itself (its labels describe a small degree of FSH activity)
Needs a working pituitaryYesYesNo
Dosing rhythmContinuous infusion lost its gonadotropin effect within 5 days; intermittent dosing held for 12Must be pulsatile; continuous exposure shuts the pituitary downEvery other day in the key trial below
US statusNot approved; in clinical trialsUS human brands discontinued; approved use today is veterinaryApproved for selected men with hypogonadism secondary to pituitary deficiency, and other uses
WADA 2026 and 2027All three banned at all times in males, section S2.2.1
Evidence gradeMediumMediumHigh

Kisspeptin: the top of the chain, and the newest data

Mutation of kisspeptin's receptor, GPR54, is associated with a failure of reproductive function, and an early study of giving kisspeptin to men came from Waljit Dhillo's group at Imperial College London. In six male volunteers, a 90-minute intravenous infusion of kisspeptin-54 against a saline control raised average LH from 4.2 to 10.8 U/L, FSH from 3.2 to 3.9 U/L, and testosterone (over 180 minutes) from 21.7 to 24.9 nmol/L. Its half-life in blood was about 28 minutes.3

The shorter form, kisspeptin-10, has been tested where it might matter clinically. In men with type 2 diabetes and low testosterone, a single intravenous dose raised LH much as it did in healthy men, and in four of them an 11-hour infusion raised LH from 3.9 to 20.7 IU/L and testosterone from 8.5 to 11.4 nmol/L, increasing the frequency of LH pulses.4 That is a study of a few men over hours, and it shows the axis in those men could still respond — not that kisspeptin is a treatment.

The 2026 data are the most useful for anyone tempted by kisspeptin as a long-term option, because they test whether the effect lasts. Subcutaneous kisspeptin-10 raised LH, FSH and testosterone in a dose-dependent way. But under continuous infusion for five days, LH and FSH fell back to the level seen with a dummy infusion, even though testosterone stayed raised; given for eight hours a day with a break, the rise in LH and FSH was still present on day 12.5 The axis adapts to a constant signal and keeps responding to an interrupted one. Kisspeptin is not approved and remains in clinical trials 1; our kisspeptin-10 entry tracks the programme.

Gonadorelin: right molecule, and the rhythm is everything

Gonadorelin is a ten-amino-acid peptide with the sequence of the body's own GnRH. Its effect depends on how it arrives: in monkeys without their own GnRH, hourly pulses restored gonadotropin secretion while a constant infusion did not, and after pulses desensitised the pituitary 1. That second effect is what GnRH agonists exploit: leuprolide, a long-acting GnRH agonist, raises testosterone at first and then, with continuous exposure, suppresses it, and is approved for advanced prostate cancer 1.

Given in pulses, GnRH can induce sperm production. In 28 men with congenital hypogonadotropic hypogonadism who had responded poorly to at least six months of injected gonadotropins, switching to pulsatile GnRH produced sperm in 17 of them, 60.7%, after about a year.6 That is a specialist treatment for a specific condition.

Gonadorelin's half-life in human studies is measured in minutes (about 2.4 minutes after an intravenous bolus) 1, so occasional injections are brief spikes rather than the regular pulses used in the trial above; we found no trial testing gonadorelin injections for preserving fertility on testosterone. Status matters too: gonadorelin's US human brands, Factrel and Lutrepulse (a pulsatile infusion product), are listed as discontinued in Drugs@FDA, and gonadorelin injections remain approved for cattle 1. Our gonadorelin entry carries the detail.

hCG: bypassing the brain, with the clearest data

hCG is a pregnancy hormone that binds the LH receptor; its labels describe its action as virtually identical to pituitary LH, and it stimulates the Leydig cells of the testis directly 1. Because it does not go through the hypothalamus or pituitary, it can work when testosterone treatment has shut that signal down, as the trial below shows.

The key experiment answers the question men on TRT most often ask. Twenty-nine healthy men were given testosterone enanthate 200 mg weekly for three weeks, with either a placebo or hCG at 125, 250 or 500 IU every other day. Testosterone from outside suppressed LH to 5% and FSH to 3% of baseline, and in the placebo group testosterone inside the testis fell by 94%, from 1,234 to 72 nmol/L. With hCG, testicular testosterone rose in step with the dose: 25% below baseline at 125 IU, 7% below at 250 IU, and 26% above at 500 IU.2 For scale, blood testosterone at baseline was 1.2% of the level inside the testis, a ratio of about 80 to 1 2, and the 2025 review below describes testosterone treatment drastically reducing testicular testosterone and impairing sperm production 7.

Two cautions keep that result in proportion. It ran for three weeks and measured hormone levels, not sperm counts or pregnancies. And hCG acts mainly on the LH receptor, with only a small degree of FSH activity on its labels 1, and the review below lists FSH as a separate option. A 2025 review in Nature Reviews Urology sets out the wider picture: testosterone treatment suppresses gonadotropins and drastically reduces testicular testosterone, recovery after stopping is slow and variable, exogenous gonadotropins including hCG and FSH may be used to preserve or restore sperm production in selected men, and testosterone is contraindicated in men actively trying to conceive.7

What hCG is actually approved for

hCG is an approved prescription drug, and its labels are specific. The Novarel and Pregnyl labels list prepubertal cryptorchidism, selected cases of hypogonadotropic hypogonadism in males — hypogonadism secondary to a pituitary deficiency — and induction of ovulation in women.8 9 Using it to preserve fertility in a man on TRT is outside those indications; the 2025 review describes it as an option for selected men.7

Both labels also open their indications section with a statement in capital letters: hCG has not been demonstrated to be effective adjunctive therapy in the treatment of obesity, with no substantial evidence that it increases weight loss beyond calorie restriction, redistributes fat, or reduces hunger.8 It is the most direct statement on any label in this article.

Matching the peptide to the problem

Put the chain and the evidence together and the comparison becomes a question of fit, not strength.

  • If the testes have failed (primary hypogonadism), none of the three can help, because each works by asking the testis to do more. The Endocrine Society guideline recommends testosterone therapy for men with symptomatic testosterone deficiency, and recommends against starting it in men planning fertility in the near term.10
  • If the pituitary is the problem, gonadorelin and kisspeptin act above the broken step and cannot work; hCG, which acts below it, can — which is exactly the use its label describes.
  • If the problem is above the pituitary, or the axis has been switched off by testosterone treatment, all three are mechanistically possible. Of the studies in this article, only hCG has controlled data on testicular testosterone in that setting, and only pulsatile GnRH has data on inducing sperm production.

Which of those applies is a diagnosis: the Endocrine Society recommends confirming low testosterone with repeated morning measurements and then evaluating the cause, not inferring it from symptoms or from a product page.10

If you are tested

WADA's 2026 List, and the 2027 List that replaces it on January 1, 2027, ban testosterone-stimulating peptides in males in a section of their own, S2.2.1, at all times in and out of competition: chorionic gonadotrophin, luteinising hormone, gonadorelin and its agonist analogues, and kisspeptin and its agonist analogues.11 12 Under the anti-doping rules, they are no alternative to testosterone for a tested athlete. Our comparison with steroids, SARMs and TRT sets them beside the other classes.

The short version

Kisspeptin, gonadorelin and hCG all raise testosterone by asking the body to make more of its own, at three different points in one chain. Kisspeptin has careful human data from a small number of men and is not approved. Gonadorelin works only in pulses, has pulsatile-treatment data in a specialist condition, and its US human brands are discontinued. hCG has the clearest evidence on the question men on TRT ask — keeping testicular testosterone up while testosterone is given — and an approved label that is narrower than the uses it is sold for.

None of that is a recommendation. It is the frame for the conversation that decides it: where in the chain the problem sits, measured rather than guessed.

Frequently asked questions

What is the best peptide to raise testosterone?

There is no single best one, because they act at different points. hCG acts on the testis and worked in a trial where testosterone had suppressed the pituitary signal; gonadorelin and kisspeptin act higher up and need a working pituitary. hCG also has the clearest controlled data. None can help when the testes themselves have failed.

Does hCG preserve fertility on TRT?

In a three-week trial in men given testosterone, low-dose hCG kept testosterone inside the testis close to normal when it otherwise fell by 94%. That measured hormone levels, not sperm or pregnancy, and hCG acts mainly as LH. Using it this way is outside its label, though a 2025 review describes it as an option for selected men.

Does gonadorelin work like hCG?

No. Gonadorelin is GnRH and acts on the pituitary, which then releases LH and FSH — but only if it arrives in pulses; continuous exposure shuts the pituitary down. hCG acts directly on the testis. Gonadorelin's US human brands are discontinued, and we found no trial of daily injections for preserving fertility on TRT.

Is kisspeptin approved?

No. It has human studies showing it raises LH, FSH and testosterone, including a 2026 trial in which intermittent dosing kept working for 12 days while continuous dosing lost its effect on LH and FSH within five, but it is not approved and remains in clinical trials.

Does hCG help with weight loss?

Its own labels say no: they state in capital letters that hCG has not been shown to be effective in treating obesity, to increase weight loss beyond calorie restriction, to redistribute fat or to reduce hunger.

Are these allowed in sport?

No. WADA bans chorionic gonadotrophin, LH, gonadorelin and its analogues, and kisspeptin and its analogues in males at all times, under section S2.2.1 of the 2026 and 2027 Lists.

Sources

  1. Grey Peptides encyclopedia entries, read October 27, 2026: kisspeptin-10 (mechanism; not approved, in clinical trials), gonadorelin (sequence; half-life 2.4 min after an IV bolus; pulse and continuous-infusion studies in monkeys; Factrel NDA 018123 and Lutrepulse NDA 019687 discontinued in Drugs@FDA; approved for cattle, 21 CFR 522.1077), leuprolide (initial testosterone rise, then suppression with continuous exposure; Lupron Depot for advanced prostate cancer) and hCG (labels: action virtually identical to LH with a small degree of FSH activity; Leydig-cell stimulation).
  2. Coviello, A. D. et al. (2005). Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. The Journal of Clinical Endocrinology and Metabolism, 90(5), 2595-2602. PMID: 15713727
  3. Dhillo, W. S. et al. (2005). Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. The Journal of Clinical Endocrinology and Metabolism, 90(12), 6609-6615. PMID: 16174713
  4. George, J. T. et al. (2013). Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. Clinical Endocrinology, 79(1), 100-104. PMID: 23153270
  5. Yeung, A. C. et al. (2026). Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men. European Journal of Endocrinology, 195(2), 206-216. PMID: 42549827
  6. Huang, Z. et al. (2024). Pulsatile gonadotropin releasing hormone therapy for spermatogenesis in congenital hypogonadotropic hypogonadism patients who had poor response to combined gonadotropin therapy. Archives of Endocrinology and Metabolism, 68, e230101. PMID: 38739523
  7. Naelitz, B. D. et al. (2025). Testosterone replacement therapy and spermatogenesis in reproductive age men. Nature Reviews. Urology, 22(10), 703-719. PMID: 40346275
  8. Novarel (chorionic gonadotropin) prescribing information, Indications and Usage (DailyMed set ac6918ff, SPL version 41, effective August 27, 2025; re-read October 27, 2026). DailyMed
  9. Pregnyl (chorionic gonadotropin) prescribing information, Indications and Usage (DailyMed set 1e94155f, SPL version 11, effective December 2, 2025; re-read October 27, 2026). DailyMed
  10. Bhasin, S. et al. (2018). Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology and Metabolism, 103(5), 1715-1744. PMID: 29562364
  11. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026, section S2.2.1 (testosterone-stimulating peptides in males). In force January 1, 2026; read October 27, 2026. WADA
  12. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2027, section S2.2.1. Dated August 26, 2026; in force January 1, 2027. WADA

This article is for education. It is not medical advice and not a guide to obtaining or using any of these drugs. Low testosterone and fertility problems are diagnosed with blood tests a clinician interprets; the right treatment depends on where in the chain the problem sits.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead